Neutral polysaccharide from Panax notoginseng enhanced cyclophosphamide antitumor efficacy in hepatoma H22-bearing mice - Liu, Yan-Hong; Qin, Hua-Yan; Zhong, Yuan-Yuan; Li, Shuang; Wang, Hua-Jing; Wang, Hong; Chen, Li-Ling; Tang, Xiang; Li, Ya-Lin; Qian, Zhong-Yi; Li, Huai-Yu; Zhang, Lei; et al. (BMC cancer, 2021)
Keywords: Animals; Antineoplastic Agents, Alkylating - pharmacology; Antitumor activity; Apoptosis; Bone marrow; Brain cancer; Cancer therapies; Carcinoma, Hepatocellular - drug therapy; Carcinoma, Hepatocellular - pathology; Cell Proliferation; Chemotherapy; Chromatography; Combined medication; Concanavalin A; Cyclophosphamide; Cyclophosphamide - pharmacology; Cytotoxicity; Deoxyribonucleic acid; DNA; Drug Synergism; Female; Hemodialysis; Hepatocellular carcinoma; Hepatocytes; Hepatoma; Humans; Humoral immunity; Immune clearance; Immune response; Immune system; Immunosuppression; Ion exchange; Laboratory animals; Life span; Liver cancer; Liver Neoplasms - drug therapy; Liver Neoplasms - pathology; Lymphocytes; Mice; Molecular weight; Myelosuppression; Natural killer cells; Neutral polysaccharide from Panax notoginseng; Panax notoginseng; Panax notoginseng - chemistry; Plant Extracts - pharmacology; Polysaccharides; Polysaccharides - pharmacology; Purification; Reagents; Spleen; Sulfuric acid; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Beijing China; China; Panax notoginseng; Liver cancer; Immunosuppression; Purification; Neutral polysaccharide from Panax notoginseng; Myelosuppression; Combined medication